Given that TROP-2 is overexpressed in 60.2% of PSCC patients and enhances PSCC cell proliferation, it might be a suitable target for ADC therapy in advanced PSCC cases. The gene discussed is TACSTD2; the disease is squamous cell carcinoma of penis.